Navigation Links
Par Pharmaceutical Reports Second Quarter 2008 Results
Date:8/7/2008

Revises 2008 Financial Guidance

New Launches Should Contribute Significantly in Second Half

WOODCLIFF LAKE, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced results for the second quarter ended June 28, 2008.

Second Quarter and Six Month Results

For the second quarter ended June 28, 2008, Par reported total revenues of $112.9 million and a net loss of $20.1 million, or $0.60 per diluted share. This is compared with reported revenues of $167.6 and net income of $2.8 million, or $0.08 per diluted share, for the same period in 2007. For the six months ended June 28, 2008, Par reported total revenues of $267.9 million and a net loss of $17.5 million, or $0.53 per diluted share. This is compared with reported revenues of $401.9 million and net income of $44.3 million, or $1.27 per diluted share, for 2007.

Patrick G. LePore, chairman, president and chief executive officer of Par said, "Contributing to the Company's disappointing financial results in the second quarter was the lack of new product launches, which is the life-line of the U.S. generics industry. However, I am still confident in our strategy and the outlook for the remainder of 2008 and beyond." Mr. LePore continued, "Our third quarter launches of dronabinol and meclizine, potential additional launches later in the year, strong pipeline of first-to-file products, and progress made in building Strativa's portfolio of innovative branded products positions the Company for long term success."

Second Quarter Financial Review

For the second quarter ended June 28, 2008, total revenues decreased 32.6% compared with the same period a year earlier as a result of increased
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
10. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
11. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... Diabetes Federation, approximately 400 million people worldwide are living ... 552 million people by 2030.  The global market for ... In 2012 approximately 330,000 people worldwide died from pancreatic ... of death due to cancer in the ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014  aTyr ... today that rare disease expert John C. McKew ... Dr. McKew brings more than two decades of expertise ... National Institutes of Health, Wyeth Research and Genetics Institute, ... lead aTyr,s efforts to expand and translate its novel ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
(Date:10/20/2014)... Oct. 20, 2014 Asterias Biotherapeutics, Inc. ... has signed a Notice of Grant Award (NGA) ... effective October 1, 2014.  The NGA provides for ... the release of additional grant funds pursuant to ... for clinical development of Asterias, product, AST-OPC1. The ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... BioLife Solutions, Inc.,(OTC Bulletin Board: BLFS), ... hypothermic storage and cryopreservation media products for ... of its new quarterly,newsletter BioPreservation Today, a ... and processes, to maximize the yield and,function ...
... Md., Jan. 26 MaxCyte, Inc., the pioneer ... the presentation of the MaxCyte(R) STX(TM) Scalable Transfection ... Session, a joint program of the Association for ... Group (LRIG). The Rapid Fire Innovation Session showcases ...
... as subcontractor to Battelle for submission of proposals ... 26 Corgenix Medical Corporation (OTC Bulletin Board: ... test kits, has announced a collaboration with Battelle, ... whose business focus includes national security. Under the ...
Cached Biology Technology:BioLife Solutions Launches BioPreservation Today(R) Industry Newsletter 2BioLife Solutions Launches BioPreservation Today(R) Industry Newsletter 3The MaxCyte(R) STX(TM) Scalable Transfection System to be Presented at the Rapid Fire Innovation Session at LabAutomation2009 2Corgenix Signs Collaboration With Battelle 2Corgenix Signs Collaboration With Battelle 3
(Date:10/19/2014)... electricity access in India over the last 30 ... carbon emissions growth during that time, according to ... Nature Climate Change ., "Energy access is fundamental ... of life, including education, communication, and health," says ... , While increased energy access is widely agreed ...
(Date:10/18/2014)... sample of patients with undiagnosed, suspected genetic conditions, a ... a higher molecular diagnostic yield than traditional molecular diagnostic ... . The study is being released to coincide with ... Exome sequencing, which sequences the protein­coding region of the ... present in a cell or organism), has been rapidly ...
(Date:10/17/2014)... for the first time how bacteria can grow directly ... the opportunity to get tremendous insights into bacteria behavior ... discovered the bacterial growth in chronic lung infections among ... by the immune cells. The researchers discovered the immune ... bacteria, forcing the bacteria to switch to a much ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... is available in German . , Four ... year,s Heinz Maier-Leibnitz Prize, Germany,s top research award for young ... the prize, which has been awarded annually by the Deutsche ... of Education and Research since 1977, that the majority of ...
... is available in German . The gene ... by cell division. It causes the production of a protein ... to 15 % of all human genes. When this gene ... is inhibited. Thereby the gene plays a decisive role in ...
... is a familiar phenomenon, even if the phrase is not: ... it around the block. After jogging regularly for a few ... three. With regular exercise, the body adapts, becoming fitter and ... oxygen to the muscles. The muscles get stronger, and so ...
Cached Biology News:Heinz Maier-Leibnitz Prizes 2009: Six young researchers recognized for outstanding achievements 2Heinz Maier-Leibnitz Prizes 2009: Six young researchers recognized for outstanding achievements 3Heinz Maier-Leibnitz Prizes 2009: Six young researchers recognized for outstanding achievements 4Heinz Maier-Leibnitz Prizes 2009: Six young researchers recognized for outstanding achievements 5Symposium to look at genetic basis of exercise 2Symposium to look at genetic basis of exercise 3
Human/Rat Neurogenin-2 MAb (Clone 7G4) Protein Family: Neural Crest Cell Markers, Transcription Factors...
Rat CINC-2 alpha/beta Affinity Purified Polyclonal Ab...
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Mouse TREM-2 Affinity Purified Polyclonal Ab...
Biology Products: